HemoGenix, Inc

HemoGenix specializes in contract services and assays for toxicity testing, stem cell research and stem cell therapeutic quality and potency testing.

12/02/2025

Early Assessment of Drug Safety Profiles

Early in vitro toxicity detection plays a critical role in the drug development process. Identifying potential toxicities at the onset of the drug discovery pipeline can prevent numerous downstream issues, particularly during clinical trials. This early assessment is essential to confirm that a preclinical candidate is viable for further development and long-term success.

Learn more: https://conta.cc/44JGLln

11/13/2025

HALO®-Tox HT: A Revolutionary Platform in Stem Cell and Bone Marrow Toxicity Testing

HALO®-Tox HT is a proprietary, fully standardized, high-throughput toxicity assay platform that has been validated according to FDA Bioanalytical Method Validation Guidelines. It incorporates two technologies:

> Suspension Expansion Culture™ (SEC™) Technology
> ATP Bioluminescence Technology

Learn more: https://www.hemogenix.com/Hemotoxicity.php

10/28/2025

Mesenchymal Cell System Toxicity

MSCGlo™-Tox HT is a fully standardized and validated ATP bioluminescence toxicity assay that measures functional viability of cells based on intracellular ATP (iATP) concentrations. MSCGlo™-Tox HT is a metabolic viability assay designed specifically for MSCs.

Learn more: https://hemogenix.com/MSC_Toxicity.php

10/02/2025

In Vitro Toxicology
Early Assessment of Drug Safety Profiles

Learn more: https://conta.cc/489WFs6

09/23/2025

Neurotoxicity Screening and Testing

Most in vitro neurotoxicity studies are performed on human iPS-derived cells in pre-coated 96- or 384-well plates. The assay platform used is called NeuroGlo™-Tox HT and is a proprietary assay based originally on the HemoGenix® HALO® Platform for stem and progenitor cell hematotoxicity screening and testing. Like the HALO® Platform, NeuroGlo™-Tox HT incorporates the most sensitive non-radioactive signal detection system available, namely ATP bioluminescence.

Learn more: https://hemogenix.com/Neurotoxicity.php

09/10/2025

In Vitro to In Vivo Concordance

Learn more: https://conta.cc/45QiGKV

08/21/2025

Eliminate the Potential of Pre-Clinical Surprises

Even with extensive measures taken to reduce unwanted and occasionally uninterpretable pre-clinical data, such issues may still arise, leading to substantial complications.

At HemoGenix®, our priority is to predict toxicity—particularly within the lympho-hematopoietic system- before unexpected pre-clinical results arise. When such challenges do occur, we are ready to support you as a trusted contract research partner.

Learn more: https://conta.cc/4oKCI0w

08/13/2025

In Vitro Primary Cell Toxicity Screening

Early in vitro screening of compounds against primary target cells can provide a wealth of information to help reduce drug development time and cost. When targeted to specific primary cell populations that might exhibit potential toxicity, such information early on in drug development, can be a game changer. In addition, in vitro assessment of drug combinations and the ability to compare toxicity profiles using the same readout, can significantly streamline the drug development process.

For more information, visit www.hemogenix.com or contact us directly at screening@hemogenix.com or by calling 719-264-6250. We look forward to assisting you.

07/30/2025

Immunotoxicity and Immune Cell Testing
https://conta.cc/41l74g2

06/24/2025

In Vitro Drug Combination and Interaction Studies

HemoGenix® provides the ability to look at the effect of drug combinations and interactive responses using primary cells and its proprietary in vitro assays. This approach allows for a more comprehensive understanding of how drugs might interact within the human body, potentially leading to more effective and safer therapeutic strategies.

Learn more: https://conta.cc/3ZNmJ7j

06/11/2025

HemoGenix has developed proprietary in vitro assays to study various aspects of the immune systems.

> HALO-Tox HT to study the effects of test compounds on common lympho-hematopoietic stem cells and progenitor cells of the T- and B-lymphocyte lineages.

> ImmunoGLO™ is an in vitro assay used to study lymphocyte proliferation or cytotoxicity.

> ImmunoGLO™-TCP is an in vitro assay platform specific for T-lymphocytes.

> ImmunoGLO™-BCP is an in vitro assay platform specific for B-lymphocytes.

> ImmunoGLO™-MLC is an in vitro 1- or 2-way mixed lymphocyte reaction platform

All of these platforms can be combined or multiplexed with flow cytometry or other readouts to study multiple facets of immunotoxicity including Cytokine Release Syndrome, Tregs, ADCC, ADC and others.

Learn more:https://hemogenix.com/Invitro_Immuno.php

06/05/2025

Mechanism of Action Studies

Knowing how and why a particular drug acts on a specific cell type or biological system is of prime importance in understanding the response. HemoGenix has the ability to study the response of specific cell populations and is also capable of investigating the Mechanism of Action (MOA) that occurs in those populations, thereby providing greater predictive toxicological information.

Learn more: https://hemogenix.com/Mechanism_of_Action.php

Address

1485 Garden Of The Gods Road, Ste 152
Colorado Springs, CO
80907

Telephone

+17192646250

Website

http://www.hemogenix.com/

Alerts

Be the first to know and let us send you an email when HemoGenix, Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Colorado Springs?